Janux Therapeutics, Inc.
JANX
$13.15
-$0.47-3.45%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -114.48M | -113.63M | -101.90M | -105.64M | -77.74M |
| Total Depreciation and Amortization | 1.98M | 2.03M | 2.07M | 2.08M | 2.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.81M | 22.65M | 19.98M | 28.05M | 25.08M |
| Change in Net Operating Assets | 12.14M | 6.71M | 9.42M | 15.72M | 4.62M |
| Cash from Operations | -77.55M | -82.24M | -70.42M | -59.79M | -46.00M |
| Capital Expenditure | -945.00K | -1.04M | -979.00K | -911.00K | -533.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.64M | -299.94M | -295.62M | -291.32M | -484.14M |
| Cash from Investing | 47.70M | -300.98M | -296.60M | -292.23M | -484.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.94M | 5.29M | 389.00M | 390.15M | 391.97M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -347.00K | -347.00K | -347.00K | -347.00K |
| Cash from Financing | 7.94M | 4.95M | 388.65M | 389.81M | 391.62M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.92M | -378.27M | 21.64M | 37.78M | -139.06M |